ERBB2 and neoplasm: To the best of our knowledge, this is the first published study that not only shows the relationship between concurrent lapatinib concentrations in plasma and tumor, but also explores the correlations between plasma/tumor drug concentrations and the phosphorylation state of lapatinib targets (HER2;EGFR), and their key co-receptor HER3.